Halozyme Therapeutics (HALO)
71.53
-0.07 (0.10%)
Upcoming Events
Latest Headlines
Form 4 HALOZYME THERAPEUTICS, For: Jun 01 Filed by: Torley Helen
June 3, 2026 8:07 PM - SEC Filing
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
June 3, 2026 9:02 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Jun 01 Filed by: Connaughton Bernadette
June 2, 2026 5:20 PM - SEC Filing
JPMorgan Reinstates Halozyme Therapeutics (HALO) at Neutral
May 20, 2026 4:31 AM - StreetInsider
Form 144 HALOZYME THERAPEUTICS, Filed by: LaBrosse Nicole
May 15, 2026 4:19 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 11 Filed by: Torley Helen
May 13, 2026 5:50 PM - SEC Filing
Increasing unusual call option volume: MRAM HALO DGXX DT SGI CM KOPN
May 13, 2026 5:40 AM - StreetInsider
Halozyme Therapeutics (HALO) PT Lowered to $93 at Morgan Stanley
May 12, 2026 8:35 AM - StreetInsider
Halozyme Therapeutics (HALO) Reiterated at Market Outperform by Citizens on Beating Q1 Estimates
May 12, 2026 5:47 AM - StreetInsider
Halozyme Therapeutics (HALO)
May 11, 2026 4:20 PM - StreetInsider
Form 144 HALOZYME THERAPEUTICS, Filed by: Torley Helen
May 11, 2026 4:11 PM - SEC Filing
Form 10-Q HALOZYME THERAPEUTICS, For: Mar 31
May 11, 2026 4:11 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: May 11
May 11, 2026 4:07 PM - SEC Filing
Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
May 11, 2026 4:03 PM - StreetInsider
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
May 11, 2026 4:01 PM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Posard Matthew L.
May 7, 2026 7:05 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Krishnan Mahesh
May 7, 2026 7:04 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Lang James Paul
May 7, 2026 7:04 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Henderson Jeffrey William
May 7, 2026 7:03 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: DUNCAN BARBARA GAYLE
May 7, 2026 7:02 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: May 05 Filed by: Connaughton Bernadette
May 7, 2026 7:02 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: May 05
May 7, 2026 4:19 PM - SEC Filing
Halozyme partners with GSK for subcutaneous cancer drug development
May 7, 2026 9:00 AM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
May 7, 2026 9:00 AM - PR NewsWire
Halozyme partners with Oruka for psoriasis drug development deal
May 6, 2026 8:01 AM - StreetInsider
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
May 6, 2026 8:00 AM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: May 01 Filed by: Connaughton Bernadette
May 5, 2026 5:05 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette
May 1, 2026 4:46 PM - SEC Filing
Halozyme to Report First Quarter 2026 Financial and Operating Results
April 30, 2026 4:30 PM - PR NewsWire
Form SCHEDULE 13G HALOZYME THERAPEUTICS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 10:40 AM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Apr 30
April 30, 2026 8:15 AM - SEC Filing
Halozyme names Darren Snellgrove as chief financial officer
April 30, 2026 8:00 AM - StreetInsider
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
April 30, 2026 8:00 AM - PR NewsWire
Halozyme Therapeutics (HALO) PT Raised to $95 at H.C. Wainwright
April 29, 2026 6:57 AM - StreetInsider
Form 8-K HALOZYME THERAPEUTICS, For: Apr 22
April 24, 2026 4:08 PM - SEC Filing
Halozyme Therapeutics (HALO) PT Raised to $96 at Morgan Stanley
April 20, 2026 8:10 AM - StreetInsider
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)
April 14, 2026 4:00 PM - BizWire
TD Cowen Reiterates Top Pick on Halozyme Therapeutics (HALO)
April 13, 2026 8:39 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Apr 06 Filed by: Torley Helen
April 7, 2026 5:15 PM - SEC Filing
Halozyme licenses drug delivery technology to Vertex for $15 million
April 7, 2026 12:35 PM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
April 7, 2026 12:35 PM - PR NewsWire
Leerink Partners on Halozyme Therapeutics (HALO): VRTX partnership 'validation of Hypercon'
April 7, 2026 11:08 AM - StreetInsider
Halozyme licenses drug delivery technology to Vertex for $15 million
April 7, 2026 8:05 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: RAMSAY DAVID A
April 2, 2026 6:29 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Torley Helen
April 2, 2026 6:29 PM - SEC Filing
Form SCHEDULE 13G/A HALOZYME THERAPEUTICS, Filed by: VANGUARD GROUP INC
March 27, 2026 9:35 AM - SEC Filing
Form 3 HALOZYME THERAPEUTICS, For: Mar 23 Filed by: RAMSAY DAVID A
March 23, 2026 6:35 PM - SEC Filing
Form ARS HALOZYME THERAPEUTICS, For: Dec 31
March 23, 2026 4:17 PM - SEC Filing
Form DEFA14A HALOZYME THERAPEUTICS,
March 23, 2026 4:13 PM - SEC Filing
Form DEF 14A HALOZYME THERAPEUTICS, For: Dec 31
March 23, 2026 4:12 PM - SEC Filing
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Funds (ETFs)
March 12, 2026 4:00 PM - BizWire
Form 8-K HALOZYME THERAPEUTICS, For: Mar 12
March 12, 2026 8:32 AM - SEC Filing
Halozyme names David Ramsay as interim CFO effective March 23
March 12, 2026 8:30 AM - StreetInsider
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
March 12, 2026 8:30 AM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: Mar 09 Filed by: Caudill Cortney
March 10, 2026 7:19 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
March 10, 2026 4:05 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
March 9, 2026 4:18 PM - SEC Filing
Full Article List
